Literature DB >> 11466620

Cdc25B activity is regulated by 14-3-3.

A Forrest1, B Gabrielli.   

Abstract

In the G2 phase cell cycle checkpoint arrest, the cdc25-dependent activation of cyclin B/cdc2, a critical step in regulating entry into mitosis, is blocked. Studies in yeast have demonstrated that the inhibition of cdc25 function involves 14-3-3 binding to cdc25. In humans, two cdc25 isoforms have roles in G2/M progression, cdc25B and cdc25C, both bind 14-3-3. Abrogating 14-3-3 binding to cdc25C attenuates the G2 checkpoint arrest, but the contribution of 14-3-3 binding to the regulation of cdc25B function is unknown. Here we demonstrate that high level over-expression of cdc25B in G2 checkpoint arrested cells can activate cyclin B/cdc2 and overcome the checkpoint arrest. Mutation of the major 14-3-3 binding site, S323, or removal of the N-terminal regulatory domain are strong activating mutations, increasing the efficiency with which the mutant forms of cdc25B not only overcome the arrest, but also initiate aberrant mitosis. We also demonstrate that 14-3-3 binding to the S323 site on cdc25B blocks access of the substrate cyclin/cdks to the catalytic site of the enzyme, thereby directly inhibiting the activity of cdc25B. This provides direct mechanistic evidence that 14-3-3 binding to cdc25B can regulate its activity, thereby controlling progression into mitosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11466620     DOI: 10.1038/sj.onc.1204574

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  26 in total

Review 1.  The rhodanese/Cdc25 phosphatase superfamily. Sequence-structure-function relations.

Authors:  Domenico Bordo; Peer Bork
Journal:  EMBO Rep       Date:  2002-08       Impact factor: 8.807

2.  Structural basis for protein-protein interactions in the 14-3-3 protein family.

Authors:  Xiaowen Yang; Wen Hwa Lee; Frank Sobott; Evangelos Papagrigoriou; Carol V Robinson; J Günter Grossmann; Michael Sundström; Declan A Doyle; Jonathan M Elkins
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-03       Impact factor: 11.205

3.  p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage.

Authors:  H Christian Reinhardt; Aaron S Aslanian; Jacqueline A Lees; Michael B Yaffe
Journal:  Cancer Cell       Date:  2007-02       Impact factor: 31.743

Review 4.  Phospho-Ser/Thr-binding domains: navigating the cell cycle and DNA damage response.

Authors:  H Christian Reinhardt; Michael B Yaffe
Journal:  Nat Rev Mol Cell Biol       Date:  2013-09       Impact factor: 94.444

Review 5.  14-3-3 proteins as signaling integration points for cell cycle control and apoptosis.

Authors:  Alexandra K Gardino; Michael B Yaffe
Journal:  Semin Cell Dev Biol       Date:  2011-09-14       Impact factor: 7.727

6.  MELK as a potential target to control cell proliferation in triple-negative breast cancer MDA-MB-231 cells.

Authors:  Gang Li; Mei Yang; Li Zuo; Mei-Xing Wang
Journal:  Oncol Lett       Date:  2018-04-20       Impact factor: 2.967

7.  14-3-3 proteins mediate inhibitory effects of cAMP on salt-inducible kinases (SIKs).

Authors:  Tim Sonntag; Joan M Vaughan; Marc Montminy
Journal:  FEBS J       Date:  2018-01-09       Impact factor: 5.542

Review 8.  Human telomerase and its regulation.

Authors:  Yu-Sheng Cong; Woodring E Wright; Jerry W Shay
Journal:  Microbiol Mol Biol Rev       Date:  2002-09       Impact factor: 11.056

9.  Wip1 confers G2 checkpoint recovery competence by counteracting p53-dependent transcriptional repression.

Authors:  Arne Lindqvist; Menno de Bruijn; Libor Macurek; Alexandra Brás; Anneloes Mensinga; Wytse Bruinsma; Olaf Voets; Onno Kranenburg; René H Medema
Journal:  EMBO J       Date:  2009-08-27       Impact factor: 11.598

Review 10.  Protein tyrosine phosphatases: structure, function, and implication in human disease.

Authors:  Lutz Tautz; David A Critton; Stefan Grotegut
Journal:  Methods Mol Biol       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.